Human PAI1 uPA complex 0.1mg
- Known as:
- Human PAI1 uPA aggregate 0.1mg
- Catalog number:
- ICPAI-UPA-0.1mg
- Product Quantity:
- 0.1mg
- Category:
- -
- Supplier:
- Innovative
- Gene target:
- Human PAI1 uPA complex 0.1mg
Related genes to: Human PAI1 uPA complex 0.1mg
- Gene:
- SERPINE1 NIH gene
- Name:
- serpin family E member 1
- Previous symbol:
- PLANH1, PAI1
- Synonyms:
- PAI
- Chromosome:
- 7q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-04-23
Related products to: Human PAI1 uPA complex 0.1mg
Related articles to: Human PAI1 uPA complex 0.1mg
- After recanalization in acute ischemic stroke, cerebral ischemia/reperfusion injury (CI/RI) drives a cascade of pathophysiological events that worsen clinical outcomes, yet effective therapeutic options remain limited. Given the neuroprotective potential of Huperzine A (HupA), the efficacy of HupA injection (HAI, a major clinical formulation of HupA) against CI/RI and its underlying molecular basis warrant investigation. - Source: PubMed
Publication date: 2026/09/09
Wang YuleXie LiGao Yue - Spatially fractionated radiotherapy (SFRT) is an emerging therapeutic strategy that enhances tumor control while reducing normal tissue toxicity. Although conventional radiotherapy is known to induce therapy-induced senescence (TIS), its induction by SFRT-particularly mini-GRID radiotherapy-remains poorly characterized. Addressing this question is essential to better understand SFRT-mediated biological responses and optimize its therapeutic potential. - Source: PubMed
Publication date: 2026/09/11
Acuña M IsabelPrados Miguel ÁngelDa Silva-Alvarez SabelaLuna-Vega VíctorKölmel Eva GSánchez-García ManuelCollado ManuelPrezado Yolanda - Macrophages play an indispensable role in the pathogenesis of aortic dissection (AD). However, the underlying molecular and cellular mechanisms remain incompletely understood. - Source: PubMed
Publication date: 2026/08/28
Li ZhenghaoChen HaonanLiu XuanyuShao YuePeng YindingWu QingchenShi HaomingZhang Cheng - To develop an interpretable machine learning model based on Diffusion-Weighted Imaging (DWI) radiomics and D-dimer for 90-day outcome prediction after intravenous thrombolysis in acute ischemic stroke (AIS), and to explore candidate upstream transcriptional programs of D-dimer using publicly available rat middle cerebral artery occlusion (MCAO) datasets as an exploratory, hypothesis-generating step. - Source: PubMed
Publication date: 2026/08/28
Bai YupengLiu QifengZhan RuonanXu QiaoqiaoXia ChunhuaQian Yinfeng - SERPINE1 encodes plasminogen activator inhibitor-1 (PAI-1), a key inhibitor of tissue-type and urokinase-type plasminogen activators. Beyond fibrinolysis, PAI-1 participates in extracellular matrix remodeling, cellular senescence, inflammatory amplification, fibrosis-like repair, metabolic stress responses, and bone-cell coupling. These processes are central to osteoporosis, osteoarthritis, and intervertebral disc degeneration, yet the role of SERPINE1/PAI-1 in skeletal tissues is highly context dependent. In osteoporosis, excessive PAI-1 activity is mainly associated with impaired osteogenesis, osteoblast-lineage senescence, defective repair, and bone loss. In osteoarthritis, PAI-1 shows a context-dependent role: persistent elevation may promote chondrocyte senescence and maladaptive matrix remodeling, whereas experimental loss-of-function studies suggest that PAI-1 may protect cartilage in specific settings by restraining excessive plasmin-MMP-mediated degradation. In intervertebral disc degeneration, emerging evidence links SERPINE1 expression and PAI-1 activity to nucleus pulposus cell senescence, fibrosis-like extracellular matrix remodeling, oxidative/metabolic stress, and matrix dysregulation. This review synthesizes current evidence and proposes a testable conceptual framework in which SERPINE1/PAI-1 may function as a stress-responsive remodeling rheostat rather than as a uniformly pathogenic or protective factor. From a translational perspective, SERPINE1/PAI-1 is unlikely to serve as a stand-alone diagnostic biomarker or a target for uniform systemic inhibition. Instead, its clinical value may lie in molecular stratification, identification of disease-stage- and compartment-specific endotypes, and locally targeted modulation of pathogenic downstream programs. Future studies should integrate spatial multi-omics, time-resolved disease models, human cohort validation, and tissue-specific delivery strategies to determine when SERPINE1/PAI-1 is therapeutically actionable in skeletal degeneration. - Source: PubMed
Publication date: 2026/09/11
Liu HangYao DengboWang YuKong Qingquan